Garcia D, Shaw RJ
Castaneda C, Marsden K, Maxwell T, Ten Eyck P, Kuwaye D, Kenne KA, et al
However, research also highlights the importance of individualized care
Challenge GLP-1 studies often require extensive participant screening, detailed medical histories, and close coordination across multiple stakeholdersfrom PI oversight to operational, regulatory, and recruitment support
Weight loss drugs have been available since the 1930s, but their popularity surged recently after the Food and Drug Administration (FDA) approved three GLP-1 receptor agonists for weight loss: Wegovy (semaglutide), Saxenda (liraglutide), and Ozempic (tirzepatide)
10.1038/s44355-025-00030-2 140 VendrellJ.El BekayR.PeralB.Garcia-FuentesE.MegiaA.Macias-GonzalezM.et al (2011)